// App-Quantinova.ai

923 : Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in Kras mutant lung cancer

Researchers

Presenter

  • Hyejin Choi

Principal Investigators

  • Jiehui Deng

  • Shuai Li

  • Tarik Silk

  • Lauren Dong

  • Elliott J. Brea

  • Sean Houghton

  • David Redmond

  • Hong Zhong

  • Jonathan Boiarsky

  • Esra A. Akbay

  • Paul D. Smith

  • Taha Merghoub

  • Kwok-Kin Wong

  • Jedd D. Wolchok

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • New York University Medical Center, New York City, NY

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Astra Zeneca, Cambridge, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed cell death protein 1

  • Cytotoxic T-lymphocyte-associated protein 4

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • selumetinib

  • Trametinib

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved